Loading...

We've got a brand new version of Simply Wall St! Try it out

Orthocell

ASX:OCC
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OCC
ASX
A$82M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • Orthocell has significant price volatility in the past 3 months.
OCC Share Price and Events
7 Day Returns
-4.5%
ASX:OCC
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
132.6%
ASX:OCC
50.9%
AU Biotechs
16.3%
AU Market
OCC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Orthocell (OCC) -4.5% 18.9% 33.8% 132.6% 18.9% 25.9%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • OCC outperformed the Biotechs industry which returned 50.9% over the past year.
  • OCC outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
OCC
Industry
5yr Volatility vs Market

Value

 Is Orthocell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Orthocell. This is due to cash flow or dividend data being unavailable. The share price is A$0.535.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Orthocell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Orthocell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:OCC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.05
ASX:OCC Share Price ** ASX (2019-11-18) in AUD A$0.54
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Orthocell.

ASX:OCC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:OCC Share Price ÷ EPS (both in AUD)

= 0.54 ÷ -0.05

-10.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orthocell is loss making, we can't compare its value to the Global Biotechs industry average.
  • Orthocell is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Orthocell's expected growth come at a high price?
Raw Data
ASX:OCC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Orthocell, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Orthocell's assets?
Raw Data
ASX:OCC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.07
ASX:OCC Share Price * ASX (2019-11-18) in AUD A$0.54
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:OCC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:OCC Share Price ÷ Book Value per Share (both in AUD)

= 0.54 ÷ 0.07

7.65x

* Primary Listing of Orthocell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orthocell is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Orthocell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Orthocell has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Orthocell expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orthocell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Orthocell expected to grow at an attractive rate?
  • Unable to compare Orthocell's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Orthocell's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Orthocell's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:OCC Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:OCC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:OCC Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -4 -6
2019-03-31 1 -4 -6
2018-12-31 1 -4 -6
2018-09-30 1 -4 -6
2018-06-30 1 -5 -6
2018-03-31 1 -3 -4
2017-12-31 1 -2 -2
2017-09-30 1 -3 -3
2017-06-30 1 -4 -4
2017-03-31 1 -4 -4
2016-12-31 1 -4 -4
2016-09-30 1 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Orthocell is high growth as no earnings estimate data is available.
  • Unable to determine if Orthocell is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:OCC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Orthocell Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OCC Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.05
2019-03-31 -0.05
2018-12-31 -0.06
2018-09-30 -0.06
2018-06-30 -0.05
2018-03-31 -0.04
2017-12-31 -0.02
2017-09-30 -0.03
2017-06-30 -0.04
2017-03-31 -0.04
2016-12-31 -0.05
2016-09-30 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Orthocell will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Orthocell's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Orthocell's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Orthocell's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Orthocell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Orthocell has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Orthocell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Orthocell's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Orthocell does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Orthocell's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Orthocell's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Orthocell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Orthocell Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OCC Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.95 -5.85 3.30 5.59
2019-03-31 0.89 -6.04 3.54 5.48
2018-12-31 0.83 -6.22 3.79 5.38
2018-09-30 0.73 -5.99 3.80 5.01
2018-06-30 0.62 -5.76 3.81 4.63
2018-03-31 0.57 -4.01 3.47 4.36
2017-12-31 0.51 -2.27 3.12 4.09
2017-09-30 0.52 -3.22 2.99 4.00
2017-06-30 0.53 -4.18 2.85 3.91
2017-03-31 0.53 -4.23 2.78 3.76
2016-12-31 0.52 -4.28 2.72 3.60
2016-09-30 0.60 -4.03 2.65 3.48
2016-06-30 0.67 -3.78 2.59 3.37
2016-03-31 0.76 -3.57 3.13 2.50
2015-12-31 0.86 -3.35 3.67 1.62
2015-09-30 0.82 -3.55 4.39 1.18
2015-06-30 0.79 -3.74 5.12 0.73
2015-03-31 0.73 -4.16 4.75 0.84
2014-12-31 0.67 -4.59 4.39 0.94
2014-09-30 0.68 -3.38 3.53 0.81
2014-06-30 0.69 -2.18 2.66 0.69
2014-03-31 0.66 -1.82 2.43 0.58
2013-12-31 0.63 -1.45 2.20 0.48
2013-09-30 0.58 -1.39 2.18 0.46
2013-06-30 0.52 -1.32 2.15 0.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Orthocell has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Orthocell has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Orthocell improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Orthocell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Orthocell has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Orthocell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Orthocell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Orthocell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Orthocell has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Orthocell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Orthocell has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Orthocell Company Filings, last reported 4 months ago.

ASX:OCC Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 10.72 0.00 11.24
2019-03-31 10.72 0.00 11.24
2018-12-31 2.69 0.00 3.50
2018-09-30 2.69 0.00 3.50
2018-06-30 2.37 0.00 2.91
2018-03-31 2.37 0.00 2.91
2017-12-31 5.12 0.00 4.92
2017-09-30 5.12 0.00 4.92
2017-06-30 4.71 0.00 5.05
2017-03-31 4.71 0.00 5.05
2016-12-31 5.96 0.00 6.07
2016-09-30 5.96 0.00 6.07
2016-06-30 4.88 0.00 5.18
2016-03-31 4.88 0.00 5.18
2015-12-31 5.99 0.00 6.11
2015-09-30 5.99 0.00 6.11
2015-06-30 4.38 0.00 4.77
2015-03-31 4.38 0.00 4.77
2014-12-31 5.38 0.00 5.72
2014-09-30 5.38 0.00 5.72
2014-06-30 0.08 0.00 3.47
2014-03-31 0.08 0.00 3.47
2013-12-31 -0.13 0.00 0.31
2013-09-30 -0.13 0.00 0.31
2013-06-30 0.21 0.00 0.59
  • Orthocell has no debt.
  • Orthocell has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Orthocell has sufficient cash runway for 2.5 years based on current free cash flow.
  • Orthocell has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 9.6% each year.
X
Financial health checks
We assess Orthocell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Orthocell has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Orthocell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Orthocell dividends.
If you bought A$2,000 of Orthocell shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Orthocell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Orthocell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:OCC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Orthocell has not reported any payouts.
  • Unable to verify if Orthocell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Orthocell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Orthocell has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Orthocell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Orthocell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Orthocell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Orthocell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Anderson
COMPENSATION A$582,275
AGE 53
CEO Bio

Mr. Paul Anderson serves as Chief Executive Officer of Orthocell Limited. Mr. Anderson has been Managing Director and Executive Director of Orthocell Limited since March 21, 2006. Mr. Anderson has over 14 yrs experience in the Medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. He has a strong track record with his previous board position with Verigen Australia Pty Ltd a human cell therapies company.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Paul's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the Orthocell management team in years:

0.8
Average Tenure
51
Average Age
  • The average tenure for the Orthocell management team is less than 2 years, this suggests a new team.
Management Team

Stewart Washer

TITLE
Executive Chairman
COMPENSATION
A$216K
AGE
49

Paul Anderson

TITLE
CEO, MD & Executive Director
COMPENSATION
A$582K
AGE
53

Matt Callahan

TITLE
Corporate Adviser
COMPENSATION
A$186K
AGE
46
TENURE
0.3 yrs

Nicole Telford

TITLE
Chief Financial Officer

Alex McHenry

TITLE
Chief Operating Officer
TENURE
0.8 yrs

Ming Hao Zheng

TITLE
Chief Scientific Officer and Member of Medical & Scientific Advisory Board

Simon Robertson

TITLE
Company Secretary
AGE
59
TENURE
7 yrs
Board of Directors Tenure

Average tenure and age of the Orthocell board of directors in years:

9.5
Average Tenure
53
Average Age
  • The tenure for the Orthocell board of directors is about average.
Board of Directors

Stewart Washer

TITLE
Executive Chairman
COMPENSATION
A$216K
AGE
49
TENURE
5.6 yrs

Paul Anderson

TITLE
CEO, MD & Executive Director
COMPENSATION
A$582K
AGE
53
TENURE
13.7 yrs

Ming Hao Zheng

TITLE
Chief Scientific Officer and Member of Medical & Scientific Advisory Board

Sam Asculai

TITLE
Chairman of Medical & Scientific Advisory Board
AGE
77

Lars Lidgren

TITLE
Independent Non-Executive Director
COMPENSATION
A$56K
AGE
76
TENURE
11.9 yrs

Ray Crowe

TITLE
Member of Medical & Scientific Advisory Board

Greg Janes

TITLE
Member of Medical & Scientific Advisory Board

David Wood

TITLE
Member of Medical & Scientific Advisory Board

Alan Wang

TITLE
Member of Medical & Scientific Advisory Board

Qi Zhou

TITLE
Non-Executive Director
COMPENSATION
A$53K
AGE
49
TENURE
7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
10. Jun 19 Buy Ming Hao Zheng Individual 18. Dec 18 06. Jun 19 7,802,339 A$0.17 A$10,271
16. May 19 Sell Stone Ridge Ventures Company 09. May 19 09. May 19 -1,960,382 A$0.54 A$-1,062,292
X
Management checks
We assess Orthocell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Orthocell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Introducing Orthocell (ASX:OCC), A Stock That Climbed 42% In The Last Year

See our latest analysis for Orthocell Orthocell recorded just AU$832,674 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. … When it reported in December 2018 Orthocell had minimal net cash consider its expenditure: just AU$355k to be specific. … Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Simply Wall St -

Does The Orthocell Limited (ASX:OCC) Share Price Tend To Follow The Market?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

How Should Investors Feel About Orthocell Limited's (ASX:OCC) CEO Pay?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Paul Anderson's Compensation Compare With Similar Sized Companies. … According to our data, Orthocell Limited has a market capitalization of AU$16m, and pays its CEO total annual compensation worth AU$597k.

Simply Wall St -

Is Orthocell Limited's (ASX:OCC) Balance Sheet A Threat To Its Future?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is OCC right in choosing financial flexibility over lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt

Simply Wall St -

One Thing To Consider Before Buying Orthocell Limited (ASX:OCC)

Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

Shareholders Should Check If Insiders Own Shares In Orthocell Limited (ASX:OCC)

A look at the shareholders of Orthocell Limited (ASX:OCC) can tell us which group is most powerful. … Orthocell is not a large company by global standards. … institutional investors have not yet purchased much of the company

Simply Wall St -

How Orthocell Limited (ASX:OCC) Can Impact Your Portfolio Volatility

If you are a shareholder in Orthocell Limited’s (ASX:OCC), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolio is important. … Broadly speaking, there are two types of risk you should consider when investing in stocks such as OCC. … The second risk is market-wide, which arises from investing in the stock market.

Simply Wall St -

Does Orthocell Limited's (ASX:OCC) Earnings Growth Make It An Outperformer?

After looking at Orthocell Limited's (ASX:OCC) latest earnings update (31 December 2017), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … Check out our latest analysis for Orthocell Did OCC's recent earnings growth beat the long-term trend and the industry? … I look at data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

Is Orthocell Limited (ASX:OCC) A Good Healthcare Bet?

However, this rate came in below the growth rate of the Australian stock market as a whole. … ASX:OCC PE PEG Gauge Nov 22nd 17 The biotech sector's PE is currently hovering around 27x, above the broader Australian stock market PE of 17x. … Although its growth has delivered lower growth relative to its biotech peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

Should You Be Concerned About Orthocell Limited's (ASX:OCC) Risks?

Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … I examine OCC’s ratio of fixed assets to total assets to see whether the company is highly exposed to the risk of this type of constraint.

Simply Wall St -

Company Info

Description

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The company’s principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment degenerative tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.

Details
Name: Orthocell Limited
OCC
Exchange: ASX
Founded: 2006
A$82,089,631
154,886,097
Website: http://www.orthocell.com.au
Address: Orthocell Limited
Murdoch University,
Building 191,
Murdoch,
Western Australia, 6150,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX OCC Ordinary Shares Australian Securities Exchange AU AUD 12. Aug 2014
CHIA OCC Ordinary Shares Chi-X Australia AU AUD 12. Aug 2014
Number of employees
Current staff
Staff numbers
0
Orthocell employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:38
End of day share price update: 2019/11/18 00:00
Last earnings filing: 2019/08/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.